GlobeNewswire Inc.··Not SpecifiedPalvella Therapeutics Secures $200M in Upsized Share Offering
Palvella Therapeutics raised $200M through upsized share offering to fund clinical development of rare disease therapies including skin disease and vascular malformation treatments.
PVLAclinical-stagepublic offering